Cancer and Leukemia Group B Leukemia Correlative Science Committee:: Major accomplishments and future directions

被引:7
作者
Bloomfield, Clara D. [1 ]
Mrozek, Krzysztof
Caligiuri, Michael A.
机构
[1] Ohio State Univ, Ctr Comprehens Canc, Div Hematol & Oncol, Dept Internal Med, Suite A455 Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA
[2] Ohio State Univ, Div Human Canc Genet, Dept Microbiol Virol Immunol & Med Genet, Columbus, OH 43210 USA
关键词
D O I
10.1158/1078-0432.CCR-06-9002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Cancer and Leukemia Group B (CALGB) Leukemia Correlative, Science Committee (LCSC) has a remarkable history of outstanding productivity and has been at the cutting edge of correlative science for adult leukemia for almost 25 years. Its work, initially focused on the use of immunophenotyping for diagnosis and prognosis of acute lymphoblastic leukemia and acute myeloid leukemia, has, for the last 15 years, focused on the clinical use of cytogenetic and molecular genetic markers in acute myeloid leukemia and acute lymphoblastic, leukemia as well as in chronic lymphocytic leukemia. Numerous CALGB,LCSC studies have had a major effect on the way we currently diagnose, predict outcome, select appropriate treatment, document complete remission, and monitor residual disease in adults with acute leukemia. In part as a result of the work. of, the CALGB LCSC, we are increasingly moving toward, molecularly targeted therapy: in acute and chronic leukemias. In this report, we briefly review those contributions from the CALGB LCSC that have had, or are likely to have in the future, a major effect on how we currently manage leukemia and outline directions of ongoing and future research conducted by the CALGB LCSC.
引用
收藏
页码:3564S / 3571S
页数:8
相关论文
共 80 条
[71]   RAS ONCOGENE ACTIVATION AND OCCUPATIONAL EXPOSURES IN ACUTE MYELOID-LEUKEMIA [J].
TAYLOR, JA ;
SANDLER, DP ;
BLOOMFIELD, CD ;
SHORE, DL ;
BALL, ED ;
NEUBAUER, A ;
MCINTYRE, OR ;
LIU, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (21) :1626-1632
[72]   Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis [J].
Thiede, C ;
Steudel, C ;
Mohr, B ;
Schaich, M ;
Schäkel, U ;
Platzbecker, U ;
Wermke, M ;
Bornhäuser, M ;
Ritter, M ;
Neubauer, A ;
Ehninger, G ;
Illmer, T .
BLOOD, 2002, 99 (12) :4326-4335
[73]   Prognostically useful gene-expression profiles in acute myeloid leukemia [J].
Valk, PJM ;
Verhaak, RGW ;
Beijen, MA ;
Erpelinck, CAJ ;
van Doorn-Khosrovani, SBV ;
Boer, JM ;
Beverloo, HB ;
Moorhouse, MJ ;
van der Spek, PJ ;
Löwenberg, B ;
Delwel, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1617-1628
[74]   Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics [J].
Virtaneva, K ;
Wright, FA ;
Tanner, SM ;
Yuan, B ;
Lemon, WJ ;
Caligiuri, MA ;
Bloomfield, CD ;
de la Chapelle, A ;
Krahe, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (03) :1124-1129
[75]  
WESTBROOK CA, 1992, BLOOD, V80, P2983
[76]   Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia:: a study of the Cancer and Leukaemia Group B [J].
Wetzler, M ;
Dodge, RK ;
Mrózek, K ;
Stewart, CC ;
Carroll, AJ ;
Tantravahi, R ;
Vardiman, JW ;
Larson, RA ;
Bloomfield, CD .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (03) :275-288
[77]  
Wetzler M, 1999, BLOOD, V93, P3983
[78]   The MLL partial tandem duplication:: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy [J].
Whitman, SP ;
Liu, SJ ;
Vukosavljevic, T ;
Rush, LJ ;
Yu, L ;
Liu, CH ;
Klisovic, MI ;
Maharry, K ;
Guimond, M ;
Strout, MP ;
Becknell, B ;
Dorrance, A ;
Klisovic, RB ;
Plass, C ;
Bloomfield, CD ;
Marcucci, G ;
Caligiuri, MA .
BLOOD, 2005, 106 (01) :345-352
[79]  
Whitman SP, 2002, BLOOD, V100, p89A
[80]  
Whitman SP, 2001, CANCER RES, V61, P7233